77 related articles for article (PubMed ID: 9066616)
1. Prognostic significance of p105 (c-erbB-2 HER2/neu) serum levels in patients with ovarian cancer.
Meden H; Marx D; Schauer A; Wuttke W; Kuhn W
Anticancer Res; 1997; 17(1B):757-60. PubMed ID: 9066616
[TBL] [Abstract][Full Text] [Related]
2. Detection of p105 (c-erbB-2, HER2/neu) serum levels by a new ELISA in patients with ovarian carcinoma.
Marx D; Fattahi-Meibodi A; Kudelka R; Uebel T; Kuhn W; Meden H
Anticancer Res; 1998; 18(4B):2891-4. PubMed ID: 9713482
[TBL] [Abstract][Full Text] [Related]
3. Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma.
Ardizzoni A; Cafferata MA; Paganuzzi M; Filiberti R; Marroni P; Neri M; Fontana V; Nicoló G; Perdelli L; Stampino CG; Rosso R; Puntoni R
Cancer; 2001 Oct; 92(7):1896-904. PubMed ID: 11745263
[TBL] [Abstract][Full Text] [Related]
4. Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer.
Bramwell VH; Doig GS; Tuck AB; Wilson SM; Tonkin KS; Tomiak A; Perera F; Vandenberg TA; Chambers AF
Breast Cancer Res Treat; 2009 Apr; 114(3):503-11. PubMed ID: 18437556
[TBL] [Abstract][Full Text] [Related]
5. Effects of interfering and influencing factors on the analyses of p105 (c-erbB-2/HER-2) oncoprotein fragment in serum.
Mielke S; Meden H; Raab T; Wuttke W; Kuhn W
Anticancer Res; 1997; 17(4B):3125-7. PubMed ID: 9329617
[TBL] [Abstract][Full Text] [Related]
6. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of the c-erbB-2 (HER2/neu) encoded oncoprotein fragment p105 in normal pregnancies.
Meden H; Mielke S; Schauer A; Kuhn W
In Vivo; 1997; 11(1):51-4. PubMed ID: 9067773
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
Müller V; Witzel I; Lück HJ; Köhler G; von Minckwitz G; Möbus V; Sattler D; Wilczak W; Löning T; Jänicke F; Pantel K; Thomssen C
Breast Cancer Res Treat; 2004 Jul; 86(1):9-18. PubMed ID: 15218357
[TBL] [Abstract][Full Text] [Related]
9. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
Sandri MT; Johansson HA; Zorzino L; Salvatici M; Passerini R; Maisonneuve P; Rocca A; Peruzzotti G; Colleoni M
Cancer; 2007 Aug; 110(3):509-17. PubMed ID: 17559147
[TBL] [Abstract][Full Text] [Related]
10. The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer.
Schippinger W; Regitnig P; Bauernhofer T; Ploner F; Hofmann G; Krippl P; Wehrschütz M; Lax S; Carney W; Neumann R; Wernecke KD; Samonigg H
Oncol Rep; 2004 Jun; 11(6):1331-6. PubMed ID: 15138574
[TBL] [Abstract][Full Text] [Related]
11. The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study.
Riener EK; Arnold N; Kommoss F; Lauinger S; Pfisterer J
Gynecol Oncol; 2004 Oct; 95(1):89-94. PubMed ID: 15385115
[TBL] [Abstract][Full Text] [Related]
12. Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival.
Chen CA; Cheng WF; Lee CN; Chen TM; Kung CC; Hsieh FJ; Hsieh CY
Gynecol Oncol; 1999 Aug; 74(2):235-40. PubMed ID: 10419737
[TBL] [Abstract][Full Text] [Related]
13. Comparison of serum HER2/neu with immunohistochemical HER2/neu expression for the prediction of biochemical progression in metastatic prostate cancer.
Tambo M; Higashihara E; Terado Y; Nutahara K; Okegawa T
Int J Urol; 2009 Apr; 16(4):369-74. PubMed ID: 19207111
[TBL] [Abstract][Full Text] [Related]
14. The correlation of c-erbB-2 oncoprotein and established prognostic factors in human breast cancer.
Sütterlin MW; Haller A; Gassel AM; Peters K; Caffier H; Dietl J
Anticancer Res; 2000; 20(6D):5083-8. PubMed ID: 11326673
[TBL] [Abstract][Full Text] [Related]
15. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
Gandour-Edwards R; Lara PN; Folkins AK; LaSalle JM; Beckett L; Li Y; Meyers FJ; DeVere-White R
Cancer; 2002 Sep; 95(5):1009-15. PubMed ID: 12209684
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
17. Hormonal treatment with sex steroids in women is associated with lower p105 serum concentrations.
Meden H; Mielke S; Marx D; Wuttke W; Kuhn W
Anticancer Res; 1997; 17(4B):3075-7. PubMed ID: 9329605
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma.
Sandri MT; Johansson H; Colleoni M; Zorzino L; Passerini R; Orlando L; Viale G
Anticancer Res; 2004; 24(2C):1261-6. PubMed ID: 15154657
[TBL] [Abstract][Full Text] [Related]
19. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
Hengstler JG; Lange J; Kett A; Dornhöfer N; Meinert R; Arand M; Knapstein PG; Becker R; Oesch F; Tanner B
Cancer Res; 1999 Jul; 59(13):3206-14. PubMed ID: 10397267
[TBL] [Abstract][Full Text] [Related]
20. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study.
Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Bock JE; Glud E; Nørgaard-Pedersen B; Høgdall CK
Cancer; 2003 Jul; 98(1):66-73. PubMed ID: 12833457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]